Article
Immunology
Snehal Shabrish, Madhura Kelkar, Reetika Malik Yadav, Umair Ahmed Bargir, Maya Gupta, Aparna Dalvi, Jahnavi Aluri, Manasi Kulkarni, Shweta Shinde, Sneha Sawant-Desai, Priyanka Kambli, Gouri Hule, Priyanka Setia, Neha Jodhawat, Pallavi Gaikwad, Amruta Dhawale, Nayana Nambiar, Vijaya Gowri, Ambreen Pandrowala, Prasad Taur, Revathi Raj, Ramya Uppuluri, Ratna Sharma, Pranoti Kini, Meena Sivasankaran, Deenadayalan Munirathnam, Ramprasad Vedam, Pandiarajan Vignesh, Aaqib Banday, Amit Rawat, Amita Aggarwal, Ujjal Poddar, Meenakshi Girish, Abhijit Chaudhary, Abhilasha Sampagar, Dharani Jayaraman, Narendra Chaudhary, Nitin Shah, Farah Jijina, S. Chandrakla, Swati Kanakia, Brijesh Arora, Santanu Sen, Madhukar Lokeshwar, Mukesh Desai, Manisha Madkaikar
Summary: Hemophagocytic lymphohistiocytosis (HLH) is characterized by immune dysregulation and systemic inflammation. In India, FHL2 and FHL3 are the most common subtypes. Genetic heterogeneity in the Indian population and poor prognosis of FHL were confirmed in this study, emphasizing the importance of flow cytometry-based assays in rapid diagnosis and validation of novel variants.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Aurora Chinnici, Linda Beneforti, Francesco Pegoraro, Irene Trambusti, Annalisa Tondo, Claudio Favre, Maria Luisa Coniglio, Elena Sieni
Summary: Hemophagocytic Lymphohistiocytosis (HLH) is a rare clinical condition characterized by sustained but ineffective immune system activation, leading to severe and systemic hyperinflammation. Prompt diagnosis and treatment are crucial for survival, as a considerable proportion of patients with HLH still die from progressive disease. Expert consultation and genetic analysis are recommended for accurate interpretation and therapeutic decisions.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Erica A. Steen, Kim E. Nichols, Lauren K. Meyer
Summary: Familial hemophagocytic lymphohistiocytosis (fHLH) is a group of rare inherited immune dysregulation disorders characterized by mutations in genes involved in cytotoxic granules in CD8+ T cells and NK cells. This defect leads to sustained lymphocyte activation and excessive secretion of pro-inflammatory cytokines, resulting in tissue damage and multi-organ failure. Studies in murine models have provided insights into the mechanisms underlying hyperinflammation in fHLH.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pediatrics
Shinsaku Imashuku, Akira Morimoto, Eiichi Ishii
Summary: HLH can be categorized as primary and secondary, with viral HLH being the major type across all age groups. Different types of HLH require specific treatment strategies, such as using immunomodulatory agents for EBV-HLH and more aggressive therapies for refractory cases.
Review
Medical Laboratory Technology
Tanya Sajan Ponnatt, Cullen M. Lilley, Kamran M. Mirza
Summary: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening disorder of immune regulation that requires rapid diagnosis and aggressive management. Understanding the pathogenesis and early diagnosis of HLH plays a crucial role in determining patient outcome. HLH can be caused by genetic mutations or acquired factors, and proper management is essential for improving prognosis.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2022)
Article
Virology
Hans Martin Orth, Andre Fuchs, Nadine Luebke, Bjoern-Erik Ole Jensen, Tom Luedde
Summary: We report an unusual case of recurrent Hemophagocytic lymphohistiocytosis (HLH) caused by Parvovirus B19 infection. The recurrent viremia triggered three episodes of hyperinflammation, two of which were clearly diagnosed as HLH. This case provides new insight into triggering mechanisms for HLH.
Article
Pediatrics
Saralee Harnchoowong, Sirisucha Soponkanaporn, Soamarat Vilaiyuk, Butsabong Lerkvaleekul, Samart Pakakasama
Summary: This study retrospectively evaluated treatment outcomes in 76 pediatric HLH patients in Thailand and found that central nervous system involvement and low platelet counts were independent predictors of early mortality.
FRONTIERS IN PEDIATRICS
(2022)
Article
Hematology
David Kuron, Jakob Christoph Voran, Friedrich Alexander von Samson-Himmelstjerna, Claudia Baldus, Ulrich Kunzendorf, Kevin Schulte, Benedikt Kolbrink
Summary: By retrospectively analyzing German HLH patients, it was found that the incidence and related mortality of HLH have significantly increased, surpassing previous expectations.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Medicine, Research & Experimental
Chiara Benevenuta, Ilaria Mussinatto, Cecilia Orsi, Fabio S. S. Timeus
Summary: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by uncontrolled and ineffective immune response, leading to hyperinflammation. This review focuses on secondary HLH in pediatric patients, discussing its epidemiology, pathophysiology, diagnosis, treatment, prognosis, as well as subtypes and new insights in diagnosis and treatment.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2023)
Article
Immunology
Julia E. Segal, Jessica D. Daley, Jessie L. Barnum, Claudia M. Salgado, Miguel Reyes-Mugica, Corinne Schneider, Serter Gumus, Darshit Thakrar, Steven W. Allen, Scott W. Canna
Summary: This case report illustrates HLH foci presenting as pulmonary/renal nodules, demonstrates the importance of monitoring a range of HLH biomarkers, and suggests the potential benefit of earlier initiation of salvage therapy.
JOURNAL OF CLINICAL IMMUNOLOGY
(2021)
Article
Immunology
Daiki Niizato, Takeshi Isoda, Noriko Mitsuiki, Shuya Kaneko, Dan Tomomasa, Takahiro Kamiya, Masatoshi Takagi, Kohsuke Imai, Michiko Kajiwara, Masaki Shimizu, Tomohiro Morio, Hirokazu Kanegane
Summary: This case report describes a new treatment approach for familial hemophagocytic lymphohistiocytosis (FHL). The study used cytokine profiles as a guide and administered dose-adjusted ruxolitinib as a bridging therapy, successfully preparing the patient for hematopoietic cell transplantation (HCT). The results demonstrate the effectiveness and safety of this treatment approach and highlight the importance of monitoring specific cytokine levels.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pediatrics
Fahad Alsohime, Mohamad-Hani Temsah, Rawan M. Alotaibi, Reham M. Alhalabi, Sarah AlEnezy, Aly Abdelrahman Yousef, Abdullah Mohammed Alzaydi, Hussam Sameer Inany, Ayman Al-Eyadhy, Mohammed Almazyad, Ali Alharbi, Abdulaziz Abdullah Alsoqati, Abdurahman Andijani, Mohammed Abu Ghazal, Kamal El Masri, Maher Doussouki, Raheel Farooq Butt, Saleh Alshehri, Mohammed Alsatrawi, Jaramia Macarambon, Gamal M. Hasan, Abdulrahman Alsultan
Summary: This study aimed to describe the clinical features, intensive care courses, and outcomes of pediatric patients diagnosed with Familial Hemophagocytic Lymphohistiocytosis (F-HLH). The results showed that fever was the most common clinical presentation, and survivors had lower rates of bleeding and required less respiratory and hemodynamic support compared to deceased patients.
FRONTIERS IN PEDIATRICS
(2023)
Article
Allergy
Yuting Tang, Qian Xu, Hui Luo, Xiaomei Yan, Gaoxiang Wang, Liang Hu, Jin Jin, David P. Witte, Rebecca A. Marsh, Liang Huang, Gang Huang, Jianfeng Zhou
Summary: This study found that the collaborative roles of IL-10 and IL-18 can drive a hyperinflammatory syndrome similar to hemophagocytic lymphohistiocytosis (HLH). The study also discovered that blocking IL-10 can be protective in patients with HLH.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Immunology
Stephanie J. Si, Sarah K. Tasian, Hamid Bassiri, Brian T. Fisher, Jasmyn Atalla, Reema Patel, Neil Romberg, Michele P. Lambert, Michele Paessler, Edward J. Behrens, David T. Teachey, Kathleen E. Sullivan
Summary: HLH is a syndrome of severe immune dysregulation with a complex diagnosis process, leading to potential delays in treatment initiation.
JOURNAL OF CLINICAL IMMUNOLOGY
(2021)
Review
Oncology
Jonathan Paolino, Nancy Berliner, Barbara Degar
Summary: HLH is a syndrome of multiorgan system dysfunction caused by hypercytokinemia and persistent activation of cytotoxic T lymphocytes and macrophages. A common finding and diagnostic criterion of HLH is cytopenias in >= 2 cell lines. The mechanism of cytopenias in HLH is multifactorial, mainly driven by suppression of hematopoiesis by pro-inflammatory cytokines.
FRONTIERS IN ONCOLOGY
(2022)
Article
Infectious Diseases
Mehdi Houssein, Ahmet Cagkan Inkaya, Cafer Balci, Mert Esme, Meliha Cagla Sonmezer, Serhat Unal, Meltem Gulhan Halil
Summary: Frailty is common among Turkish people living with HIV and is associated with higher morbidity and mortality rates.
Article
Public, Environmental & Occupational Health
Gokhan Metan, Omrum Uzun, Gulcin Telli Dizman, Meliha Cagla Sonmezer, Ahmet Cagkan Inkaya, Gulsen Hazirolan, Murat Akova, Serhat Unal
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2022)
Article
Medicine, General & Internal
Ezgi Aysu Sahin, Deniz Mavi, Emre Kara, Meliha Cagla Sonmezer, Ahmet Cagkan Inkaya, Serhat Unal
Summary: This study analyzed the changes in inflammatory markers among people living with HIV (PLWH) treated with different antiretroviral regimens over a period of two years. The results showed that treatment with integrase inhibitors was associated with a favorable inflammatory marker profile among PLWH in the two-year follow-up. These favorable inflammatory characteristics may contribute to the prevention of non-communicable diseases (NCD) among PLWH.
POSTGRADUATE MEDICINE
(2022)
Article
Immunology
Meliha Cagla Sonmezer, Gulcin Telli Dizman, Enes Erul, Taha Koray Sahin, Tugba Saricaoglu, Alparslan Alp, Mine Durusu Tanriover, Omrum Uzun, Serhat Unal, Murat Akova
Summary: Vaccines, such as CoronaVac and BNT162b2, have shown effectiveness in preventing symptomatic COVID-19 cases. The third dose of these vaccines can provide further protection against severe COVID-19. It is important to prioritize the administration of third-dose boosters as an effective strategy in combating the pandemic.
Review
Microbiology
Semra Aydin, Gamze Varan, Serhat Unal
Summary: Synthetic peptides are useful tools for studying proteins and developing vaccine candidates. However, they have low immunogenicity capacities and are susceptible to enzymatic degradation. By using a multiepitope approach and an appropriate adjuvant/carrier system, the immunogenicity capacities of synthetic peptides can be enhanced.
FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI
(2022)
Meeting Abstract
Oncology
D. C. C. Guven, F. G. Gulbahce Incesu, H. C. Yildirim, E. Erul, E. Chalabiyev, B. Y. Aktas, D. Yuce, Z. Arik, S. Kilickap, S. Aksoy, M. Erman, K. M. Hayran, S. Unal, A. Alp, O. Dizdar
ANNALS OF ONCOLOGY
(2022)
Article
Medicine, General & Internal
Ahmet Gorkem Er, Alberto Antonio Romero Alonso, Ignacio Marin-Leon, Abdullah Sayiner, Stefano Bassetti, Kutay Demirkan, Patrick Lacor, Hartmut Lode, Wiktoria Lesniak, Mine Durusu Tanriover, Ali Fuat Kalyoncu, Nicolas Merchante, Serhat Unal
Summary: This document provides a simple and reliable updated guide for clinical decision-making in the management of complex patients with multimorbidity and CAP in the real-life setting.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Oncology
Deniz Can Guven, Fatma Gul Gulbahce Incesu, Hasan Cagri Yildirim, Enes Erul, Elvin Chalabiyev, Burak Yasin Aktas, Deniz Yuce, Zafer Arik, Saadettin Kilickap, Sercan Aksoy, Mustafa Erman, Kadir Mutlu Hayran, Serhat Unal, Alpaslan Alp, Omer Dizdar
Summary: This study aimed to evaluate the seroconversion rates after two doses of inactive COVID-19 vaccine (CoronaVac) and the benefit of a third dose mRNA vaccine booster in patients with cancer receiving active treatment. The results showed that cancer patients had lower antibody levels and seropositivity rates after two doses of CoronaVac compared to the control group. However, the seroconversion rate significantly increased and antibody titers improved after administering a third dose of an mRNA vaccine. Administering a third dose of mRNA vaccine can effectively improve the immunogenicity of CoronaVac in cancer patients receiving active treatment.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Infectious Diseases
Meliha Cagla Sonmezer, Taha Koray Sahin, Enes Erul, Gulcin Telli Dizman, Ahmet Cagkan Inkaya, Alparslan Alp, Sehnaz Alp, Serhat Unal
Summary: This study investigated the burden of common human coronaviruses (HCoVs) in a hospital setting over a five-year period. The results showed that HCoVs can cause respiratory tract infections, and co-infection with rhinovirus was the most common. These findings have important implications for the control and prevention of respiratory infections.
JAPANESE JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Taha Koray Sahin, Enes Erul, Melek Seren Aksun, Meliha Cagla Sonmezer, Serhat Unal, Murat Akova
Summary: This study surveyed 283 physicians in Turkey about their knowledge, attitude, concerns, and vaccine acceptance for monkeypox. The results showed that 32.5% of the physicians had a good level of knowledge and 31.4% planned to have the monkeypox vaccine. Female physicians and older individuals were more likely to be knowledgeable about monkeypox. Physicians from internal medicine divisions, those who learned about monkeypox during medical school or residency, and those previously exposed to COVID-19 had a higher knowledge score of monkeypox. Physicians with a good knowledge score were more worried about monkeypox compared to COVID-19.
Article
Oncology
Nesligul Ozdemir, Burak Y. Y. Aktas, Ahmet Gulmez, Ahmet C. C. Inkaya, Aygin Bayraktar-Ekincioglu, Saadettin Kilickap, Serhat Unal
Summary: This study aimed to assess the impact of clinical pharmacists' education on pneumococcal vaccination rate in cancer patients. The results showed that education provided by clinical pharmacists significantly increased the pneumococcal vaccination rate in cancer patients.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Microbiology
Caglayan Merve Ayaz, Nesrin Damla Karakaplan, Ahmet Cagkan Inkaya, Banu Cakir, Serhat Unal, Pinar Zarakolu
Summary: The aim of this study was to investigate the frequency of Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and Mycoplasma genitalium in men living with HIV. The study found that young age, having multiple partners, drug use, and exchanging sex for money/drugs were associated with STI infection.
MIKROBIYOLOJI BULTENI
(2023)
Article
Critical Care Medicine
Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola
Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.
Article
Medicine, General & Internal
Imran Hasanoglu, Rahmet Guner, Ilhami Celik, Fikret Kanat, Ayse Batirel, Gulcin Telli Dizman, Esma Eren, Dilek Yildiz Sevgi, Ilkay Bozkurt, Kadriye Kart Yasar, Sevtap Senoglu, Esra Kazak, Ridvan Karaali, Aysel Celikbas, Husnu Pullukcu, Arif Atahan Cagatay, Serhat Unal, Sebnem Erdinc, Fehmi Tabak, Ahmet Gul, Emine Alp
Summary: This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. The study found that remdesivir is a safe and well-tolerated drug, and older age, low SpO(2) level on admission, tachycardia, and ICU admission are independently associated with increased mortality among patients with moderate/severe COVID-19 receiving remdesivir treatment.
TURKISH JOURNAL OF MEDICAL SCIENCES
(2022)
Article
Medicine, General & Internal
Ahmet Ilbay, Mine Durusu Tanriover, Iskin Pinar Zarakol, Ezgi Caliskan Guzelce, Hatice Bolek, Serhat Unal
Summary: This study found a prevalence of 3.5% for pertussis in adults, which may be easily overlooked or misdiagnosed. Patients with pertussis commonly experienced paroxysmal cough with an average duration of 20 days. These findings indicate that pertussis remains a health problem in adults, suggesting that childhood vaccination may not be sufficient to prevent infection in adults.
TURKISH JOURNAL OF MEDICAL SCIENCES
(2022)